Artelo Biosciences Secures $6.5 Million via At‑the‑Market Offering, Broadening Its Cash Position

Artelo’s latest financing is a classic ATM transaction – a flexible, on‑demand sale of common stock under Rule 415(a)(4). The company sold about 5.49 million shares, each at $1.19, for an aggregate gross proceeds of $6,530,000. The filing does not disclose a net‑proceeds figure, but the 3.0% commission paid to sales agent H.C. Wainwright & Co., LLC suggests that net cash will be slightly lower after underwriting fees.

Pricing in context Unlike a traditional IPO that sets a price range in a preliminary prospectus, Artelo’s ATM supplement did not reference any prior price band. Consequently, there is no “high‑end” or “low‑end” signal to read into the $1.19 price. The figure simply reflects the market price at which the shares were sold on the day of the offering, indicating that the company was able to place the equity without a discount that would have signaled weak demand.

Who is selling the stock? UBS is listed as the lead underwriter in the cover‑page metadata, while H.C. Wainwright & Co., LLC acts as the exclusive sales agent, handling the day‑to‑day execution of the ATM. No other syndicate members are named, underscoring the relatively small scale of the raise.

What will Artelo do with the cash? The prospectus supplement is blunt: management retains “broad discretion” to apply the net proceeds for general corporate purposes. The filing does not break out allocations for R&D, debt repayment, or acquisitions. In practice, that language gives the board latitude to fund ongoing clinical programs, bolster working capital, or shore up the balance sheet as needed.

Risks that come with the money The filing flags several offering‑related concerns that investors should weigh: - Dilution: New investors will experience an accretion of $0.12 per share after expenses, but existing shareholders will see their ownership percentage reduced. - Nasdaq compliance: Artelo warns that failure to meet listing standards could trigger a delisting, eroding liquidity and raising future financing costs. - Going‑concern uncertainty: The broader risk factors reiterate that the company’s ability to continue operating hinges on securing sufficient capital for clinical trials and commercialization. - Overallotment: The supplement does not disclose an overallotment option, leaving the size of the offering fixed at the disclosed share count.

Market backdrop ATM offerings have become a favored tool for small‑cap biotech firms that need incremental funding without the publicity of a full secondary offering. Industry observers note that such raises tend to be modest in size and priced close to the prevailing market, mirroring Artelo’s approach. The $6.5 million infusion, while not transformative, provides a runway that could help the company avoid a cash crunch and keep its pipeline on schedule.

Bottom line Artelo’s ATM raise is a low‑key, execution‑focused move rather than a headline‑grabbing capital event. By pricing the shares at $1.19 and securing $6.5 million in gross proceeds, the company has added a modest cash buffer while keeping dilution and Nasdaq‑listing risks front and center for investors.